The Dutch founder mutation SDHD.D92Y shows a reduced penetrance for the development of paragangliomas in a large multigenerational family.
Germline mutations in SDHD predispose to the development of head and neck paragangliomas, and phaeochromocytomas. The risk of developing a tumor depends on the sex of the parent who transmits the mutation: paragangliomas only arise upon paternal transmission. In this study, both the risk of paraganglioma and phaeochromocytoma formation, and the risk of developing associated symptoms were investigated in 243 family members with the SDHD.D92Y founder mutation. By using the Kaplan-Meier method, age-specific penetrance was calculated separately for paraganglioma formation as defined by magnetic resonance imaging (MRI) and for paraganglioma-related signs and symptoms. Evaluating clinical signs and symptoms alone, the penetrance reached a maximum of 57% by the age of 47 years. When MRI detection of occult paragangliomas was included, penetrance was estimated to be 54% by the age of 40 years, 68% by the age of 60 years and 87% by the age of 70 years. Multiple tumors were found in 65% and phaeochromocytomas were diagnosed in 8% of paraganglioma patients. Malignant paraganglioma was diagnosed in one patient (3%). Although the majority of carriers of a paternally inherited SDHD mutation will eventually develop head and neck paragangliomas, we find a lower penetrance than previous estimates from studies based on predominantly index cases. The family-based study described here emphasizes the importance of the identification and inclusion of clinically unaffected mutation carriers in all estimates of penetrance. This finding will allow a more accurate genetic counseling and warrants a 'wait and scan' policy for asymptomatic paragangliomas, combined with biochemical screening for catecholamine excess in SDHD-linked patients.
Hensen
Erik F
EF
Department of Otolaryngology and Head and Neck Surgery, Leiden University Medical Center, Albinusdreef 2, PO-box 9600, Leiden 2300 RC, The Netherlands. e.f.hensen@lumc.nl
Jansen
Jeroen C
JC
Siemers
Maaike D
MD
Oosterwijk
Jan C
JC
Vriends
Annette Hjt
AH
Corssmit
Eleonora Pm
EP
Bayley
Jean-Pierre
JP
van der Mey
Andel Gl
AG
Cornelisse
Cees J
CJ
Devilee
Peter
P
D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D019943:Amino Acid Substitution / Q000235:genetics*; D005191:Family Characteristics; D005260:Female; D018703:Founder Effect; D006801:Humans; D008297:Male; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D010235:Paraganglioma / Q000453:epidemiology / Q000235:genetics*; D010375:Pedigree; D019683:Penetrance; D013385:Succinate Dehydrogenase / Q000235:genetics*; D055815:Young Adult
C491545:SDHD protein, human; D013385:Succinate Dehydrogenase